Claire Corcoran
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Journal: Molecular cancer
Published: January 31, 2025
Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Journal: Molecular cancer
Published: October 01, 2024
Design, synthesis and biological evaluation of a novel bioactive indane scaffold 2-(diphenylmethylene)c-2,3-dihydro-1H-inden-1-one with potential anticancer activity.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: February 08, 2023
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 23, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2021
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Journal: The New England journal of medicine
Published: September 21, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 04, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 13, 2019
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 03, 2017
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
Journal: PloS one
Published: December 24, 2015
Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 17, 2014
Last Updated: 09/26/2026